Lefamulin

Indications

Lefamulin is used for: Indicated for treatment of, community-acquired bacterial pneumonia (CABP), in adults caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydophila pneumoniae

Adult Dose

Community Acquired Bacterial Pneumonia Indicated for treatment of community-acquired bacterial pneumonia (CABP) in adults caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae 150 mg IV q12hr OR 600 mg PO q12 hr Duration of treatment: 5-7 days

Child Dose

Renal Dose

Administration

Contra Indications

Lefamulin should not be used in patients with known hypersensitivity to lefamulin or any other members of the pleuromutilin antibiotic class, or any of the components of Xenleta.

Precautions

Lefamulin has the potential to cause a change on an ECG reading (prolonged QT interval). Patients with prolonged QT interval, patients with certain irregular heart rhythms (arrhythmias), patients receiving treatment for certain irregular heart rhythms (antiarrhythmic agents), and patients receiving other drugs that prolong the QT interval should avoid lefamulin.

Pregnancy-Lactation

Pregnancy Based on animal studies, may cause fetal harm Verify pregnancy status in women of reproductive potential before starting treatment Animal studies Animal studies indicate that IV administration during organogenesis resulted in an increased incidence of prenatal mortality at mean maternal exposures 0.9 times the mean exposure in clinical patients (based on AUC[0-24h]), decreased fetal body weights, apparent delay in sexual maturation that suggests treatment-related developmental delay, and malformations Contraception Advise females of reproductive potential to use contraception during treatment and for 2 days after final dose Lactation No data are available on the presence of lefamulin in human milk, the effects on the breastfed infant, or the effects on milk production Available data in animals have shown lefamulin excreted in milk If a drug is present in animal milk, it is likely the drug will be present in human milk Owing to the potential for serious adverse effects, instruct lactating women to pump and discard milk for the duration of treatment and for 2 days after final dose

Interactions

Side Effects

Side effects of Lefamulin : The most common adverse reactions reported in patients taking lefamulin included diarrhea, nausea, reactions at the injection site, elevated liver enzymes and vomiting.

Mode of Action

First-in-class semi-synthetic pleuromutilin antibiotic; selectively inhibits bacterial translation by binding to the peptidyl transferase component of the ribosome 50S subunit